FDA enforcement is changing—and API (active pharmaceutical ingredient) and bulk ingredient manufacturers are feeling the impact at the border. Shipments that once cleared without issue are now being detained for compliance gaps that are entirely preventable. In many cases, the problem is not complex regulatory failure—it’s missing or incorrect information in FDA registrations and listings.
We guide companies through these requirements every day, and we’re seeing a clear pattern: small oversights are leading to costly delays, disrupted supply chains, and increased scrutiny from FDA.
The Most Common Reasons FDA Is Detaining Shipments
- Missing U.S. Importer Information
Manufacturers must register their facilities with FDA and list their U.S. Importer as part of that registration.
We’re seeing this as the most frequent issue at the port:
- The importer is not listed at all
- The information is outdated
When this happens, FDA cannot link the shipment to a compliant supply chain.
How to stay compliant:
Update your establishment registration with accurate U.S. Importer details before your product ships—not after it arrives.
- Bulk Ingredients Not Properly Listed
Bulk drug substances must be listed with FDA before they are imported.
Common problems include:
- The ingredient is not listed
- The listing is incomplete or inactive at the time of shipment
- Labelling lacks required statements
FDA is increasingly enforcing this requirement, especially for API suppliers.
How to stay compliant:
Make sure every bulk ingredient you ship is actively listed and fully compliant before it reaches the port.
- Manufacturer Registration Gaps
FDA requires both:
- Facility registration
- Inclusion of the manufacturer in drug listing submissions
We often see:
- Manufacturers that are not registered
- Outdated facility information named on listing files
These disconnects raise immediate red flags during import review.
How to stay compliant:
Confirm that your registration and listing data are aligned—and that every manufacturer in your supply chain is properly documented.
- Increased Enforcement Across the Board
FDA is no longer treating certain shipments as low-risk.
Products that historically moved through customs without issue are now being stopped—especially:
- Bulk ingredients
- API shipments
This shift reflects a broader move toward stricter, more consistent enforcement.
What this means to you:
Past clearance does not guarantee future compliance. Every shipment must be validated before it ships.
- Missing or Incorrect NDC Package Sizes
This is one of the fastest-growing causes of detention.
Each drug product must have a unique National Drug Code (NDC) for every package size and type:
- The third segment of the NDC identifies the package configuration
We’re seeing shipments detained because:
- Additional sizes were never listed
- NDCs were not assigned for each configuration
How to stay compliant:
Assign and list a separate NDC for every package size and package type—including bulk configurations.
- Inaccurate or Outdated Listing Data
FDA is paying closer attention to data accuracy across submissions.
Even when listings exist, issues arise when:
- Information is inconsistent
- Data is outdated
- Details do not match shipment documentation
How to stay compliant:
Review and update your listing data regularly. Accuracy is now a key enforcement focus.
- Expanding Focus on Animal Drug APIs
These requirements apply to animal drug APIs as well.
The FDA’s Center for Veterinary Medicine (CVM) is:
- Increasing enforcement
- Focusing on bulk ingredient compliance
Recent reports show a significant rise in detentions tied to veterinary products, particularly due to:
- Not listing bulk ingredients
- Missing additional package sizes in listings
How to stay compliant:
Apply the same level of control and verification to animal drug APIs as you do for human drug products.
What’s Driving the Increase in Detentions?
We’re seeing three clear trends behind the surge:
- Stricter enforcement of existing regulations under 21 CFR Part 207
- New expectations for package size-specific NDCs, even for bulk ingredients
- Industry misinformation about listing and registration requirements
FDA isn’t rewriting the rules—but it is enforcing them more consistently and more aggressively.
How Registrar Corp Helps You Avoid Detentions
Regulatory compliance can be complicated—but it doesn’t have to be.
Registrar Corp’s expert OTC drug regulatory specialists guide you through FDA requirements with the clarity and precision needed to keep your shipments moving. Our team understands how FDA evaluates registrations and listings at the port—and we help you meet those expectations before your products ship.
Here’s how we support you:
We Get Your Registrations Right
We complete and maintain your FDA Drug Establishment Registration, ensuring:
- Your U.S. Importer is correctly listed
- Your information stays current as your supply chain evolves
This reduces the risk of immediate flags during import review.
We Build Accurate, Complete Listings
We help you list your drug products and bulk ingredients correctly, including:
- Verifying that all APIs and bulk substances are listed
- Ensuring every manufacturer is properly included
- Keeping listings active and aligned with your shipments
This prevents the most common causes of detention.
We Assign and Manage NDCs Properly
NDC errors are one of the fastest-growing enforcement issues.
We:
- Assign NDCs for each package size and configuration
- Ensure your listings reflect all variations, including bulk formats
This keeps your products aligned with FDA’s current expectations.
We Review and Validate Your Data
Even small inconsistencies can delay your shipment.
We:
- Audit your listing data for accuracy
- Identify gaps before FDA does
- Help you correct issues quickly and correctly
This proactive approach helps you avoid costly delays.
We Keep You Ready for What’s Next
FDA enforcement continues to evolve—especially for APIs and animal drug products.
We stay ahead of regulatory changes so you don’t have to:
- Monitoring enforcement trends
- Identifying new risk areas
- Guiding you on what FDA expects now—not last year
Conclusion
The increase in FDA detentions is not random—it’s the result of tighter enforcement and higher expectations.
The good news: most of these issues are entirely preventable.
When you take a proactive approach—verifying registrations, confirming listings, and ensuring data accuracy—you reduce risk, avoid delays, and keep your supply chain moving. A trusted regulatory partner like Registrar Corp understands how FDA enforces the rules in real-world scenarios. We guide you through the details so you can ship with confidence, stay compliant, and focus on growing your business.
Contact Registrar today for more information or to start you compliance journey.
